PT - JOURNAL ARTICLE AU - Megan M. Niedzwiecki AU - Shoshannah Eggers AU - Anu Joshi AU - Georgia Dolios AU - Alejandra Cantoral AU - Héctor Lamadrid-Figueroa AU - Chitra Amarasiriwardena AU - Martha M. Téllez-Rojo AU - Robert O. Wright AU - Lauren Petrick TI - Lead exposure and serum metabolite profiles in pregnant women in Mexico City AID - 10.1101/2021.06.03.21258309 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.03.21258309 4099 - http://medrxiv.org/content/early/2021/06/08/2021.06.03.21258309.short 4100 - http://medrxiv.org/content/early/2021/06/08/2021.06.03.21258309.full AB - Background Lead (Pb) exposure is a global health hazard causing a wide range of adverse health outcomes. Yet, the mechanisms of Pb toxicology remain incompletely understood, especially during pregnancy. To uncover biological pathways impacted by Pb exposure, this study investigated serum metabolomic profiles during the third trimester of pregnancy that are associated with blood Pb and bone Pb.Methods We used data and specimens collected from 99 women enrolled in the Programming Research in Obesity, Growth, Environment, and Social Stressors birth cohort based in Mexico City. Maternal Pb exposure was measured in whole blood samples from the third trimester of pregnancy and in the tibia and patella bones at 1 month postpartum. Third-trimester serum samples underwent metabolomic analysis; metabolites were identified based on matching to an in-house analytical standard library. A metabolome-wide association study was performed with all three Pb measurements using multiple linear regression models, adjusted for confounders and batch effects. Class enrichment analyses were also conducted.Results The median (interquartile range) blood Pb concentration was 2.9 (2.6) μg/dL. Median bone Pb, measured in the patella and tibia, were 2.5 (7.3) μg/g and 3.6 (9.5) μg/g, respectively. Of 248 total metabolites identified in serum, 31 were associated with blood Pb (p<0.05). Class enrichment analysis identified significant overrepresentation of metabolites classified as fatty acids and conjugates, amino acids and peptides, and purines. Tibia and patella Pb were associated with 14 and 11 metabolites, respectively (p<0.05). Comparing results from bone and blood Pb, glycochenodeoxycholic acid and glycocholic acid were negatively associated with blood Pb and tibia Pb, while 5-aminopentanoic acid and 7-methylguanine were negatively associated with blood Pb and patella Pb. One metabolite, 5-aminopentanoic acid, was associated with all three Pb measures.Conclusion This study identified serum metabolites in pregnant women associated with Pb measured in blood (31 metabolites) and bone (tibia: 14 metabolites, patella: 11 metabolites). These findings provide insights on the metabolic profile around Pb exposure in pregnancy and may provide important links to guide detailed studies of toxicological effects for both mothers and children.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Institutes of Health (R01 ES014930, R01 ES013744, P30 ES023515, U2CES030859, T32 HD049311, R01 ES031117, R21 ES030882) and the National Institute of Public Health/Ministry of Health of Mexico.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Procedures were approved by institutional review boards at the Harvard School of Public Health, Icahn School of Medicine at Mount Sinai, and the Mexican National Institute of Public Health.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the PROGRESS study team (PI: Robert O. Wright), but restrictions apply to the availability of these data. Data are available upon reasonable request.(AdA)adrenic acid(ALA)alpha-linolenic acid(AA)arachidonic acid(BMI)body mass index(DGLA)dihomo-gamma-linolenic acid(DHA)docosahexaenoic acid(DPA)docosapentaenoic acid(ENT)effective number of tests(ETA)eicosatetraenoic acid(EPA)eicosapentaenoic acid(GLA)gamma-linolenic acid(IQR)interquartile range(Pb)lead(LA)linoleic acid(LC-HRMS)liquid chromatography high-resolution mass spectrometry(Instituto Mexicano del Seguro Social – IMSS)Mexican Social Security System(‘pooled QC’)pooled quality control sample(PCs)principal components(PROGRESS)Programming Research in Obesity, Growth, Environment, and Social Stressors(RP)reverse phase(SDA)stearidonic acid